Navigation Links
Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
Date:9/13/2010

rter of fiscal 2010.  The increase in R&D expenses in 2011 was mainly due to costs associated with the development and testing of the Company's four drug compounds and the acquisition of Tumorgrafts as the Company continues to expand its tumorgraft platform.

General and administrative expenses for first quarter of fiscal 2011 were $738,000 as compared to $806,000 in fiscal 2010.  The decrease was primarily attributable to the Company's consolidation of its operations to Baltimore, Maryland.

For the first quarter of fiscal 2011, the Company reported a net loss of $591,000, or ($0.02) per share, compared to a net loss of $1.0 million, or ($0.03) per share, in the corresponding quarter of fiscal 2010.  In addition to the factors described above, the Company's net losses reflect non-cash expenses, i.e., share-based compensation and depreciation, of $180,000 or ($0.01) per share, in the first quarter of 2011 compared to $58,000, or ($0.00) per share, in the first quarter of 2010.

The Company's cash position on July 31, 2010 was $2.1 million compared to $2.6 million on April 30, 2010.

First Quarter Highlights:

  • Experienced an increase in top-line revenues of 66% with overall gross margins increasing from 31% to 66%, year-over-year;
  • Experienced year-over-year top-line revenue growth of 679% in the Preclinical eValuation business;
  • Continued to expand its Biomerk Tumorgraft platform to approximately 350 tumorgrafts which are available and/or in development at July 31, 2010, representing all of the major solid tumor indications;
  • Hired a Preclinical Sales Director to oversee direct sales of Preclinical eValuation services; and
  • Began to offer genome sequencing as part of its Personalized Oncology services.

  • David Sidransky, M.D., Chairman of the Board of Champions Biotechnology, Inc., noted, "The 2011 first quarter results are positive.  As we move into 2011, we continue to see
    '/>"/>

    SOURCE Champions Biotechnology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
    2. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
    3. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
    4. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
    5. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
    6. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
    7. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
    8. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
    9. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
    10. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
    11. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... , July 29, 2015  AsureQuality and Ubiquitome ... testing for applications in food and primary production ... powered real-time PCR device, the Freedom4. ... through to the supermarket shelf for producers, processors ... involvement in animal disease control and pest management ...
    (Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
    (Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for ... current system received a score of 0 (range -10 to +10) for its impact ... Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes ...
    (Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
    Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
    ... consortia comprised of top domestic automakers is pushing development ... with a focus on improving battery power in low ... company to provide the right chemistry. , ,The ... energy storage technologies operating under the FreedomCAR and ...
    ... week, as British authorities broke up a plot to smuggle ... travelers, new regulations means more checked baggage, if only to ... at their destinations (Im envisioning a new business opportunity in ... of security, well all wait a little longer at baggage ...
    ... - In rural Wisconsin, one company is earning their ... , IsoTropic Networks, Inc. , a global satellite communications ... iDirect Technologies , a satellite-based broadband access provider. , ... support center set on 21 acres in rural Wisconsin, ...
    Cached Biology Technology:Johnson Controls partnership wins new contract 2Johnson Controls partnership wins new contract 3Opportunities rise from travel chaos 2Rural company works to improve broadband 2
    (Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
    (Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
    (Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
    Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
    ... The Eureka E! 2692 Molecular Tests project has developed ... robustness of the immune system in poultry. The test ... from poultry houses, using equipment already available in poultry ... and take weeks ?providing information too late to be ...
    ... change the action of 60 percent of currently available ... effective, according to an article published in the April ... the potential to improve treatments for diseases including heart ... a new way to manipulate perhaps the most important ...
    ... Institute have identified a molecular interaction that triggers a ... attacking this target with selective drugs might improve treatment. ... a team led by Qunyan Yu, MD, and Peter ... of a certain mutated oncogene and the newly described ...
    Cached Biology News:Faster immune system testing set to improve poultry quality 2Study in Science holds promise for a new approach to drug therapy 2Study in Science holds promise for a new approach to drug therapy 3Study in Science holds promise for a new approach to drug therapy 4Study in Science holds promise for a new approach to drug therapy 5New cellular flaw found in some virulent breast cancers 2New cellular flaw found in some virulent breast cancers 3
    Request Info...
    Highly sensive assay for detecting apoptosis in living cells. See detailed descriptions above in K250-25....
    ... The Z-Competent E. coli Transformation Buffer ... of competent E. coli cells for simple ... method completely eliminates the requirement for heat ... transformation can be performed by adding DNA ...
    ... 400 Spun Columns, 10. *SizeSep 400 Spun ... 400 base pairs in length. - ... and pre-equilibrated in distilled water containing 0.15% Kathon ... ~ 400 base pairs. *Extremely useful ...
    Biology Products: